手法を比較

	児童不安尺度（MASC-2）は、8歳から19歳までの子供および青年における不安症状の39項目自己記入式評価尺度である。	Children's Yale-Brown Obsessive Compulsive Scale（小児Yale-Brown強迫症スケール）
分野	児童精神医学	児童精神医学
系統	Process / pipeline	Process / pipeline
提唱年	1997	1997
提唱者	John March	Lawrence Scahill, Mark Riddle, W. Goodman (Y-BOCS)
種類	Self-report questionnaire	Clinician-administered semi-structured interview
原典	March, J. S., Parker, J. D. A., Sullivan, K., Stallings, P., & Conners, C. K. (1997). The Multidimensional Anxiety Scale for Children (MASC): Factor structure, reliability, and validity. Journal of the American Academy of Child & Adolescent Psychiatry, 36(4), 554–565.	Scahill, L., Riddle, M. A., McSwiggin-Hardin, M., Ort, S. I., King, R. A., Goodman, W. K., . . . Leckman, J. F. (1997). Children's Yale-Brown Obsessive Compulsive Scale: Reliability and validity. Journal of the American Academy of Child & Adolescent Psychiatry, 36(6), 844–853.
別名	MASC, MASC-2	CY-BOCS, Y-BOCS-Children
関連	3	3
概要	The Multidimensional Anxiety Scale for Children (MASC-2) is a 39-item self-report measure of anxiety symptoms in children and adolescents ages 8–19 years. Developed by John March and colleagues in 1997, the MASC operationalizes anxiety as a multifaceted construct comprising physical symptoms, social anxiety, harm avoidance, and separation/panic concerns. The revised MASC-2 (2012) improved psychometric properties and clinical utility. It is widely used in clinical and research settings for screening, diagnosis, and outcome measurement in childhood anxiety disorders.	The Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) is a 10-item clinician-administered semi-structured interview for assessing obsessive-compulsive symptoms in children and adolescents ages 6–17 years. Developed by Scahill, Riddle, and colleagues in 1997 as a child adaptation of the adult Y-BOCS, the CY-BOCS quantifies severity of obsessions and compulsions, insight, resistance, and functional impact. It is the gold-standard outcome measure in pediatric OCD research and clinical practice for diagnosis, severity rating, and treatment monitoring.